Wall Street Zen Downgrades Sana Biotechnology (NASDAQ:SANA) to Sell

Sana Biotechnology (NASDAQ:SANA) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report released on Saturday.

SANA has been the subject of several other research reports. Wedbush raised their target price on shares of Sana Biotechnology from $5.00 to $6.00 and gave the stock an “outperform” rating in a report on Friday, November 7th. Citigroup reissued an “outperform” rating on shares of Sana Biotechnology in a research note on Thursday, October 30th. Bank of America upped their target price on Sana Biotechnology from $6.00 to $7.00 and gave the company a “buy” rating in a research note on Tuesday, January 6th. HC Wainwright reduced their price target on Sana Biotechnology from $11.00 to $9.00 and set a “buy” rating on the stock in a report on Friday, November 7th. Finally, JMP Securities set a $8.00 price objective on Sana Biotechnology in a report on Thursday, October 30th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $8.14.

Sana Biotechnology Stock Performance

NASDAQ SANA opened at $3.93 on Friday. The business’s 50 day moving average price is $4.54 and its 200-day moving average price is $4.14. Sana Biotechnology has a fifty-two week low of $1.26 and a fifty-two week high of $6.55. The company has a market cap of $1.05 billion, a P/E ratio of -4.05 and a beta of 1.96.

Sana Biotechnology (NASDAQ:SANA) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.18) by $0.03. As a group, equities analysts predict that Sana Biotechnology will post -1.16 EPS for the current year.

Institutional Investors Weigh In On Sana Biotechnology

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Baillie Gifford & Co. lifted its holdings in shares of Sana Biotechnology by 13.6% in the 3rd quarter. Baillie Gifford & Co. now owns 11,436,503 shares of the company’s stock worth $40,600,000 after buying an additional 1,371,775 shares during the period. Vanguard Group Inc. raised its holdings in shares of Sana Biotechnology by 19.9% in the third quarter. Vanguard Group Inc. now owns 9,128,973 shares of the company’s stock valued at $32,408,000 after acquiring an additional 1,517,474 shares in the last quarter. Marex Group plc purchased a new stake in Sana Biotechnology in the second quarter worth about $10,423,000. JPMorgan Chase & Co. grew its holdings in Sana Biotechnology by 180.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 2,135,444 shares of the company’s stock worth $7,581,000 after acquiring an additional 1,375,029 shares in the last quarter. Finally, Integral Health Asset Management LLC increased its position in Sana Biotechnology by 33.3% during the 3rd quarter. Integral Health Asset Management LLC now owns 2,000,000 shares of the company’s stock valued at $7,100,000 after purchasing an additional 500,000 shares during the period. 88.23% of the stock is owned by institutional investors.

Sana Biotechnology Company Profile

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.